Interleukin-l 1 (IL-11) is a novel multifunctional hematopoietic cytokine capable of stimulating cells of the myeloid, lymphoid, erythroid, and megakaryocytic lineages in vitro. We have tested the pleiotropic properties of this cytokine on the hematopoietic recovery of mice after a combined regimen of sublethal irradiation and carboplatin administration. This regimen results in severe myelosuppression. characterized by a prolonged period of thrombocytopenia and severe anemia. Administration of recombinant human IL-l1 (rhlL-11; 250 pg/kg/d) had multilineage effects on bone marrow and spleen hematopoietic activity, increasing the number of megakaryocyte, erythroid, granulocyte. and I NTERLEUKIN-1 1 (IL-1 1) is a multifunctional hematopoietic cytokine that was originally identified in conditioned medium from an IL-1 -stimulated primate stromal cell line and was subsequently cloned using the TI 165 cell line as a bioassay.' Considerable data has since accumulated indicating that rhIL-l1 acts synergistically with other growth factors to stimulate multiple lineages of hematopoietic cells in vitro. In combination with IL-3 or Steel factor, recombinant human IL-I I (rhIL-11) supports the formation of primitive human blast cell colonies from CD34+DR-bone marrow cells.' Similarly, in combination with IL-3 or IL-4, rhIL-l1 supports the formation of blast cell colonies derived from murine bone marrow enriched for stem cells with 5-fl~orouracil.~~~
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NTERLEUKIN-1 1 (IL-1 1) is a multifunctional hematopoietic cytokine that was originally identified in conditioned medium from an IL-1 -stimulated primate stromal cell line and was subsequently cloned using the TI 165 cell line as a bioassay.' Considerable data has since accumulated indicating that rhIL-l1 acts synergistically with other growth factors to stimulate multiple lineages of hematopoietic cells in vitro. In combination with IL-3 or Steel factor, recombinant human IL-I I (rhIL-11) supports the formation of primitive human blast cell colonies from CD34+DR-bone marrow cells.' Similarly, in combination with IL-3 or IL-4, rhIL-l1 supports the formation of blast cell colonies derived from murine bone marrow enriched for stem cells with 5-fl~orouracil. ~~~ The reported effects of rhIL-l1 administration on erythropoiesis to date have been paradoxical. In combination with Steel factor or IL-3, rhIL-1 1 promotes erythroid burst formation in vitro, a result that could also be achieved by the combination of IL-3 and IL-11 even in the absence of erythr~poietin.~ However, although the addition of rhIL-l I to a human long-term bone marrow assay was found to enhance the expansion of both myeloid and mixed colonies derived from these cultures, there was no apparent effect on erythroid progenitors in the nonadherent cell population in this study. 6 A number of reports have described multiple effects of rhIL-1 l on megakaryocytopoiesis in rhIL-1 1 synergizes with IL-3 to stimulate bone marrow megakaryocyte progenitors (colony-forming unit megakaryocyte [CFU-MEG])' and has been shown to have direct effects on enriched megakaryocytes, increasing both size and ploidy in the absence of other growth an effect that was also observed in the presence of neutralizing antibodies to IL-6.7*L0 These findings suggest that rhIL-l1 may be an important factor involved in the in vivo regulation of hematopoiesis and, in particular, megakaryocytopoiesis. Although rhIL-1 l has no apparent B-cell growth factor activity, rhIL-1 I has been shown to stimulate Ig, producing B cells both in vitro and in vivo.'.'L The ability of rhIL-l l to stimulate B cells is dependent on the presence of CD4' T cells and is partially inhibited by an antibody to IL-6."
Results from recent studies have shown that rhIL-l1 is macrophage progenitors compared with the vehicletreated controls. This was reflected in the peripheral circulation by a reduction of both the platelet and hematocrit nadirs and a significantly reduced period ofthrombocytopenia and anemia in the rhlL-l l-treated mice. The results from this study support the broad spectrum of biologic activities that have been attributed to rhlL-l1 in vitro and suggest that this cytokine may be an effective agent in the treatment of myelosuppression associated with cancer chemotherapy and bone marrow transplantation. 0 l994 by The American Society of Hematology.
active when administered as a single agent in vivo. In both normal and splenectomized mice, administration of rhIL-1 1 results in a marked stimulation of megakaryocytopoiesis, increasing the number of megakaryocyte progenitors, stimulating megakaryocyte endoreplication, and increasing the peripheral platelet count.I3 Similar results have been reported after rhIL-1 1 administration to rats, with a dose-dependent increase in platelet counts and a corresponding increase in bone marrow megakaryocyte size and p l~i d y . '~ In sublethally irradiated bone marrow transplanted mice, rhIL-1 1 enhanced both platelet and neutrophil recovery, indicating that rhIL-l1 can have multilineage effects on hematopoiesis in vivo."
Murine models of myelosuppression have been widely used to study the effects of cytokine administration on hematopoietic recovery. Such regimens include 5-flUOrOuracil16 and cycl~phosphamide'~ administration. These methods of myelosuppression produce only modest thrombocytopenia (40% to 50% reduction in circulating platelet counts), with the platelet nadir typically occumng 6 to 7 days after myelosuppression. The usefulness of such regimens for assessing the therapeutic potential of hematopoietic cytokines with thrombopoietic activity is limited, and is further complicated by the period of rebound thrombocytosis associated with these drugs. We have developed a model of myelosuppression in mice using a combined regimen of sublethal irradiation and carboplatin administration. This regimen produces a severe and prolonged period of thrombocytopenia with no rebound thrombocytosis, making it a more suitable model for assessing the hematopoietic activity and thrombopoietic potential of rhIL-1 1.
MATERIALS AND METHODS
Myelosuppressive regimen and rhIL-I I administration. Female C57BL/6 mice, IO to 12 weeks old (Jackson Laboratories, Bar Harbor, ME), were housed five to a cage and supplied standard rodent chow diet and water ad libitum. Mice received 500 cGy sublethal irradiation from a '"CS source followed by a single injection of the chemotherapeutic drug Carboplatin (1.2 mg/mouse intraperitoneally [IP]; Bristol Myers Squibb, Cambridge, MA). rhIL-I 1 (Genetics Institute, Cambridge, MA) was purified from Escherichia coli and administered by subcutaneous injection. To determine an optimal dose of rhIL-11 for this study, naive mice were injected with increasing doses of rhIL-l1 and peripheral platelet counts were measured. From this study, a dose of 250 pg/kg/d, which gave maximal platelet increases, was chosen for administration to myelosup pressed mice.
rhIL-1 1 was administered by subcutaneous injection in two doses of 125 pg/kg each (administered morning and afternoon) in sterile saline containing 0.5% homologous mouse serum. rhIL-l1 treatment was started 1 day after myelosuppression and was continued for 20 days. Control animals received an equal volume of vehicle alone. In each experiment, 15 mice were assigned to an experimental group and 5 mice were bled from each group on designated days in an alternating manner such that no individual mouse was bled more than once a week. The results for the peripheral hematology represents pooled data from three separate experiments (n = minimum of IO mice for each time point). Mice were killed on day I5 (during the period of severe myelosuppression) and on days 30 or 34 (when peripheral platelet and red blood cell [RBC] counts had recovered). Hematopoietic progenitor assays were performed on pooled samples from 5 mice from each experimental group. To allow for the inherent variation associated with hematopoietic progenitor assays, aged-matched naive mice were killed on the same day and progenitor assays set up in parallel for comparison with data from the myelosuppressed mice. The progenitor data shown are from one experiment and are representative of the results obtained from three separate experiments performed at nadir and two separate experiments after recovery. In additional experiments, administration of rhIL-I 1 was delayed until day 3 or day 7 after myelosuppression and the recovery of peripheral platelets compared with that seen in either mice administered rhIL-1 1 commencing on day I or to vehicle-treated controls.
Peripheral hematology. Peripheral blood was drawn from the retroorbital sinus into EDTA/Heparin-coated capillary tubes and immediately transferred into EDTA-coated blood tubes. Automated hematologic analysis was performed on 20 pL of blood using a Baker 9000 hematology analyzer (Serono Baker Diagnostics, Allentown, PA) with mouse-specific discriminator settings. The analyses performed were platelet counts, RBC counts, white blood cell (WBC) counts, and hematocrit. In one study (n = 5 mice for each time point), the percentage of circulating reticulocytes was measured by flow cytometry using Thiazole Orange staining by a previously published method.'* Quantitation ofbone marrow and spleen progenitors. The number of burst-forming units-erythroid (BFU-E) and colony-forming units granulocyte/macrophage (CFU-GM) were determined using single-cell suspensions from pooled bone marrow or spleen samples in CATCH buffer consisting of 0.38% sodium citrate (Fisher, Fair Lawn, NJ), 2 X mol/L theophylline, and I X lo-' mol/L adenosine (Sigma, St Louis, MO) in Hanks' Balanced Salt Solution (HBSS), pH 7.2, supplemented with 3% bovine serum albumin (BSA) and 1 pg/mL prostaglandin El (Sigma). Either 5 X IO4 bone marrow cells or 5 X IO5 spleen cells were added to 0.9% methylcellulose supplemented with 30% fetal bovine serum (FBS), 1 .25% Lglutamine, 1 U/mL erythropoietin, 100 U/mL granulocyte-macro- rhlL-l 1 was administered subcutaneously at the designated dosage for 7 days. Mice were bled and peripheral platelets were quantitated as described in Materials and Methods. Data are presented as mean 2 SD (n = 5).
Abbreviation: ND, not determined.
phage colony-stimulating factor (GM-CSF), and 10% WEHI-3b conditioned medium in a final volume of 1 mL. Cultures were incubated for 7 days at 37'C in 5% COz and 95% humidified air. Colonies were defined as discrete clusters of cells containing greater than 50 cells. Bone marrow and spleen CFU-MEG were quantitated as previously described.13 Briefly, either 1 X IO5 bone marrow cells or 1 X IO6 spleen cells were added to a mixture of 0.325% agar and modified McCoy's 5A media supplemented with 10% FBS, 10% WEHI3b as a source of IL-3 and 30 U/mL of rhIL-l1 in a final volume of I mL. Control wells contained the same volume of medium in place of the WEHI-3b and rhIL-l I . Plates were incubated for 6 days at 37°C in 5% CO2, 95% humidified air. The wells were then air-dried and megakaryocytes were stained for acetylcholinesterase. Colonies were defined as discrete clusters of cells containing three or more positively stained cells. Peripheral hematology after combined modality treatment. The combined regimen of sublethal irradiation and carboplatin resulted in severe myelosuppression with a prolonged period of thrombocytopenia. Circulating platelet counts in the vehicle-treated controls reached a nadir on day 12 (95 X 106/mL) and remained substantially reduced for a period of 6 to 8 days. Administration of rhIG 1 1 commencing 1 day after the myelosuppressive treatment diminished the platelet nadir (210 X lo6, day 10) and decreased the extent and duration ofthrombocytopenia (Fig l) , with periph- era1 platelet counts returning to pretreatment levels by day 20, compared with day 24 in the vehicle-treated controls.
RESULTS

Dose response to
The combination of sublethal irradiation and carboplatin also resulted in a steady decline in the hematocrit, which reached the nadir on day 18 (18%) and recovered to near normal by day 24 in the vehicle controls. In contrast, the hematocrit nadir in mice treated with rhIL-1 1 occurred earlier (day 14) and was less severe (25%) (Fig 2) . Hematocrit values in these mice returned to normal by day 20. RBC counts in both groups of mice were consistent with the changes seen in hematocrit (data not shown). In one study, circulating reticulocytes were measured using Thiazole Orange staining and flow cytometric analysis. Results from these studies demonstrated an increase in circulating reticulocytes that preceded the hematocrit recovery and occurred approximately 1 week earlier in the mice treated with rhILl l than in the vehicle-treated controls (Fig 3) .
All mice suffered from severe leukopenia that lasted for more than l month. Administration of rhIL-l1 had no effect on either the nadir or the recovery time course of the WBC count.
rhlL-l1 stimulates bone marrow and spleen hematopoiesis. On day 15, during myelosuppression and on days 30 or 34, when platelet counts and hematocrit had recovered, mice from each experimental group were killed and progenitor assays were performed as described in Materials and
Methods. On day 15, there was a modest increase in bone marrow cellularity in the rhIL-l l-treated mice reiative to vehicle-treated controls (19.4 X lo6 cells/femur for naive mice, l 1.3 X lo6 cells/femur for vehicle-treated mice, and 14.7 x lo6 cells/femur for rhIL-l l-treated mice). In the rhIL-l l-treated mice, there was a significant increase in the number of bone marrow BFU-E, CFU-GM, and CFU-MEG compared with that of vehicle-treated controls ( Fig   4A, B, and C , respectively, P < .O I ). By day 30, bone marrow cellularity in both experimental groups was comparable to that in naive mice (data not shown). However, although the number of CFU-GM and BFU-E in the bone marrow of vehicle-treated mice showed signs of recovery from values obtained on day 15, there remained a significant reduction in the number of myeloid and erythroid progenitors relative to naive mice (50% and 40%, respectively, P < .01; Fig 4A  and B, respectively) . In contrast, recovery in the rhIL-11-treated mice was such that the number of bone marrow 
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I T ministration began 1 day after the combined modality regimen of sublethal irradiation and carboplatin chemotherapy. We examined whether delaying treatment had any effect on the ability of rhIL-l1 to accelerate hematopoietic recovery in this model. The data in Fig 5 show that delaying treatment until day 3 postirradiation/chemotherapy reduced the ability of rhIL-l I to accelerate platelet recovery, with this effect being most apparent between days 9 and 15. Delaying treatment with rhIL-l1 until day 7 completely abrogated platelet activity in this model. Delayed dosing had similar detrimental effects on the ability of rhIL-l1 to accelerate the recovery of RBC count and hematocrit (data not shown).
DISCUSSION
IL-1 1 is a multifunctional hematopoietic cytokine whose major in vitro biologic activities result from synergistic interactions with other growth factors. Current experimental data suggest that rhIL-1 1 has a key role in the regulation of hematopoiesis, and is capable of stimulating cells from the myeloid, erythroid, and megakaryocytic lineages. In vivo administration of rhIL-l 1 to naive mice predominantly effects cells of the megakaryocyte lineage, increasing the number of bone marrow CFU-MEG, stimulating megakaryocyte endoreplication, and increasing peripheral platelet counts.13 Although IL-6 has been shown to have similar in vivo megakaryocytic stimulatory IL-6 could not be detected in serum of naive mice treated with rhIL-1 1 (Neben et all3 and C . Quinto, unpublished observation). Similarly, in mice transplanted with bone marrow cells infected with a recombinant retrovirus bearing the cDNA for human IL-1 1 and expressing high levels of rhIL-I 1 protein, peripheral platelet counts were elevated in the absence of detectable IL-6 mRNA in the spleen.22 These results argue against a role for IL-6 in mediating the thrombopoietic activities of rhIL-1 1.
To evaluate further the activity of rhIL-I I , we have studied the effects ofthis cytokine on the hematopoietic recovery of mice treated with a combined regimen of low-dose irradiation and carboplatin administration. Carboplatin was specifically chosen because it has been shown to cause marked thrombocytopenia in humans.23 This regimen resulted in severe myelosuppression with a prolonged period of thrombocytopenia and anemia. A platelet nadir of less than 10% normal values was reached 12 days after the treatment and platelet counts remained less than 20% of control values for a period of 8 days. The severity of thrombocytopenia resulting from this regimen far exceeds that induced by the administration of 5-fluorouracil, which typically causes a modest (40% to 50%) reduction in platelet counts lasting 3 to 4 days.16 The myelosuppressive effects of carboplatin were confirmed by administration of a higher dose (1.8 mg) after the sublethal irradiation. This resulted in such severe myelosuppression that the vehicle-treated controls failed to recover after being bled at the platelet nadir (day 12). Interestingly, the therapeutic potential of rhIL-l1 was still apparent in this regimen, because the mice treated with rhIL-l1 survived (J. Leonard, unpublished observation). For this comparative study it was necessary to use the lower dose ( I .2 mg) of carboplatin. This combination provided us BFU-E and CFU-GM were similar to the number of myeloid and erythroid progenitors in naive mice and significantly higher than the corresponding values in the vehicletreated controls (Fig 4A and B , respectively, P < .01). In contrast, the number of megakaryocyte progenitors in the bone marrow declined between days 15 and 34 and remained significantly reduced compared with naive animals despite the recovery of peripheral platelet counts (Fig 4C, P   < . O l) . However, the number of megakaryocyte progenitors in mice treated with rhIL-11, although reduced compared with naive controls, was significantly increased compared with the vehicle-treated mice (Fig 4C, P < .01 ).
Mice treated with rhIL-1 I and killed on day I5 had increased spleen weights and cellularity ( l06 X IO6 cells/ spleen for naive mice, 20 X IO6 cells/spleen for vehicletreated mice, and I52 X IO6 cells/spleen for rhIL-1 I -treated mice), and increased numbers of splenic BFU-E, CFU-GM, and CFU-MEG compared with both the naive mice and vehicle-treated controls (Fig 4D, E, and F, respectively, P < . O 1). Compared with the vehicle-treated controls, splenic hematopoietic progenitors in the rhIL-1 l-treated mice were increased approximately 60-, 45-, and IO-fold for BFU-E, CFU-GM, and CFU-MEG, respectively. By days 30 and 34, splenic hematopoietic activity in the both the vehicletreated controls and the rhIL-1 I -treated mice was comparable with that of naive controls. The multilineage stimulation of bone marrow and splenic hematopoiesis in the rhIL-l l-treated mice 15 days after myelosuppression is consistent with the accelerated recovery of platelet counts and hematocrit observed in these mice.
Analysis of alternative dosing regimens for rhIL-l1 administration. In all the above experiments, rhIL-l I ad- with a prolonged period ofthrombocytopenia in the absence effects on hematopoietic recovery, reducing the extent and of a rebound thrombocytosis, making the model especially duration of both thrombocytopenia and anemia. Furtherattractive for assessing the biologic activity of a cytokine more, rhIL-1 l -treated mice had increased numbers of bone such as rhlL-11, which is known to be a potent stimulator marrow myeloid, erythroid, and megakaryocytic progeniof megakaryocytopoiesis.
tors during the period of platelet and hematocrit recovery. Therapeutic treatment with rhIG 1 I after sublethal irraThere was also a dramatic increase in splenic hematopoiesis diation and carboplatin administration had significant in mice treated with rhIL-I 1 15 days after myelosuppres- 
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sion. Previous studies have shown that, after sublethal irradiation, mice display a burst of splenic hematopoietic activity that can be enhanced by the addition of ~ytokines.'~ However, the importance of splenic hematopoiesis to peripheral hematologic recovery is not clear. Whether increased splenic hematopoiesis reflects the stimulation of resident hematopoietic stem cells in the spleen or the mobilization of cells from the bone marrow is difficult to determine rigorously. Nonetheless, in this study it was clear that the increase in splenic hematopoietic activity in the rhIL-l l-treated mice was not at the expense of the bone marrow, as cellularity and bone marrow progenitors (BFU-E, CFU-GM, and CFU-MEG) were all increased compared with that of vehicle-treated controls. These findings are consistent with previous studies showing that the effect of rhIL-1 1 administration on megakaryocyte progenitors, endoreplication, and platelet production is similar in normal and splenectomized mice.13
The ability of rhIL-1 1 to reduce the severity of the platelet nadir marks an apparent difference between the in vivo biologic activities of rhIL-1 1 and IL-6. Although administration of IL-6 has been shown to increase platelet counts in V~V O , '~-~' treatment with IL-6 after sublethal irradiation or 5-fluorouracil administration in mice or sublethal irradiation in dogs failed to reduce the platelet nadir, even though platelet recovery was accelerated in all case^?^-*^ A number of studies have reported similar stimulatory effects for both rhlL-l l and IL-6 on CFU-MEG-derived colonies when used in combination with IL-3, suggesting equivalent activities at this stage of megakaryocyte d e~e l o p m e n t . " '~~~"~~ In contrast, stimulation of the earliest recognizable megakaryocyte progenitor, the BFU-MEG, has only been demonstrated for rhIL-l If one assumes that in cases of severe myelosuppression, early megakaryocyte differentiation is required to initiate the platelet response, the ability of rhIL-1 I to regulate megakaryocytopoiesis at multiple levels of de- velopment may account for the reduced platelet nadir and accelerated platelet recovery observed in these mice. In this context, it is interesting to note that the combination of IL-3, a well-documented early acting megakaryocytic growth factor, and IL-6 was effective in reducing the platelet nadir after 5-fluorouracil administration.16 However, neither IL-3 alone nor IL-6 alone had any effect on the platelet nadir. The observation in this study that rhIL-l 1 administered as a single agent was capable of reducing the platelet nadir and accelerating platelet recovery supports a pivotal role for ILl l in the regulation thrombopoiesis in vivo.
In separate experiments we examined the effects of delaying the start of rhIL-l1 administration after myelosuppression on the subsequent recovery of peripheral platelets. The results from these experiments demonstrated that the ability of rhIL-l1 to affect the platelet nadir was only seen when rhIL-l1 administration began 1 day after myelosuppression, and not when rhIL-1 1 administration was delayed until day 3 or 7. These data indicate that rhIL-1 1 must be present early after myelosuppression to ameliorate the platelet nadir, and suggest that an early interaction with a population of responsive progenitors is essential to achieve this result. In this context, preliminary studies indicate that beginning treatment with rhIL-1 1 on the same day as combined modality regimen may provide some additional benefit; however, further studies will be necessary to determine if these effects are statistically significant.
In naive mice, administration of rhIL-l1 at a dose that stimulates megakaryocytopoiesis and platelet production has no effect on either the hematocrit or the circulating reticulocyte count.13 Similarly, administration of rhIL-l1 to lethally irradiated, bone marrow transplanted mice accelerates the recovery of peripheral platelet and neutrophil counts but has no effect on the hematocrit or RBC recovery." In this study, administration of rhIL-l1 to myelosuppressed mice had significant effects on the erythroid lineage, For personal use only. on November 11, 2017 . by guest www.bloodjournal.org From reducing the severity and duration of the anemia relative to vehicle-treated controls. Mice treated with rhIL-l1 had increased numbers of erythroid progenitors in the bone marrow and spleen compared with the vehicle-treated controls 15 days after myelosuppression. In addition, quantitation of circulating reticulocytes by flow cytometric analysis demonstrated a profound reticulocytosis before the hematocrit recovery, which occurred approximately l week earlier in the rhIL-l l-treated mice than in the vehicle-treated controls. These results suggest that the accelerated hematocrit recovery in mice treated with rhILl1 is the result of enhanced erythropoietic activity. Similar effects of rhIL-l1 on erythroid recovery have been reported in a murine model ofbone marrow transplantation in which mice received syngeneic bone marrow that had been retrovirally infected with the human IL11 cDNA.~'
The results from this study demonstrate the ability of rhIL-1 1 administration to reduce the platelet nadir and accelerate peripheral platelet recovery after a severe myelosuppressive regimen. This recovery appears to be caused, at least in part, by the stimulation of the early stages of megakaryocytopoiesis. Furthermore, the effects of rhIL-1 l in this study were not restricted to the megakaryocyte lineage. Mice that received rhIL-l1 displayed signs of marked stimulation of erythropoiesis that reduced the seventy of anemia and accelerated the recovery of the hematocrit. Although rhIL-1 I had no effect on leukocyte recovery, stimulation of both bone marrow and spleen CFU-GM was apparent in the treated mice, suggesting a potential for combination therapy with G-CSF or GM-CSF. The results from this study s u p port the broad spectrum ofbiologic activities that have been attributed to this cytokine in vitro and suggest that rhIL-l1 may prove effective in the treatment of myelosuppression associated with cancer chemotherapy and bone marrow transplantation.
